Industries · B2B healthcare · Pharma

A pharma marketing agency for companies too specialized for the big networks

For emerging biopharma, CROs, CDMOs and pharma tech: senior marketers who understand MLR review, HCP audiences and long pharma sales cycles, without the overhead of a network agency.

Senior specialists, hourly billing you can see line by line, and a 30-day cancellation notice. Your first call is with a co-founder.

350+
webinar sign-ups for Cradle, which sells AI protein design to pharma R&D teams, with 30% from its top-tier target accounts. You can read the rest of our client results on our customers page.
Healthcare and life science companies we've helped

Pharma in 2026, by the numbers

68%
of clinical trial starts in 2025 came from emerging biopharma companies, up from 56% in 2019 (IQVIA, 2026)
46%
of US novel drug launches from 2020 to 2024 were filed by emerging biopharma companies (IQVIA, 2025)
70-80
novel drugs expected to launch worldwide each year over the next five years (IQVIA, 2026)
14.8
days on average for a life sciences promotional asset to clear review, up from 13.8 the year before (Vodori, 2025)
The job

Why pharma marketing needs a specialist

Pharma buyers, and the regulators behind them, expect a level of rigor that most general agencies have never had to work to.

Every asset goes through MLR review

Medical, legal and regulatory reviewers sit between every draft and the market. In Vodori's 2025 benchmark, a video took 32 days on average to get approved, so a campaign planned without that time misses its window.

Physicians tune out promotion

HCPs filter out anything that reads like an ad and listen to data and to each other. In a study of nearly 12,000 physicians, peer adoption strongly predicted who started prescribing a new drug.

Service contracts need a committee

A CRO or CDMO deal needs sign-off from R&D, procurement and quality. Each group reads your materials looking for a different risk, and one weak answer can stall the whole decision.

The rules change at every border

FDA's OPDP in the US, the ABPI Code in the UK and the EFPIA code across Europe each shape what you can claim, so one global campaign rarely runs unchanged in every market.

Problems we solve

Problems we solve for pharma companies

What founders and commercial leads in pharma and pharma services tell us, and how we respond.

“We launch our first product next year and have no marketing team.”
What we hear
We act as your marketing function through launch, covering positioning, HCP messaging, the launch website and the first campaigns, while you hire the permanent team.
What we do
“Every campaign spends six weeks in MLR review.”
What we hear
We build a claims library your reviewers approve once, write every asset against it and plan the calendar around review, so assets go through in fewer rounds.
What we do
“Our new business depends on two BD directors and their contacts.”
What we hear
We run account-based marketing into the sponsors you want to win, so your BD team calls people who have already seen your science and your track record.
What we do
“We need to enter the US, and nobody there knows us.”
What we hear
We adapt your positioning and claims to the new market's rules, then bring content and campaigns to its buyers before your commercial team arrives.
What we do
“Our scientists block anything that simplifies the data.”
What we hear
Our writers work from your papers and datasets, and your scientists see drafts early, so the content stays accurate enough for them and clear enough for buyers.
What we do
“A network agency gave us a junior team and a large invoice.”
What we hear
Your account is led by a senior Head of Growth, and you pay hourly for the specialists the work actually needs that month.
What we do

Approach

Pharma marketing services built around compliance

Your Head of Growth plans five workstreams around medical, legal and regulatory review, for emerging biopharma and the companies that sell to pharma.

MLR-ready claims and workflows

Together with your medical and regulatory team, we build a claims library that records every claim, its supporting reference and the channels it is cleared for. Templates are agreed with your reviewers up front, so review checks each asset against claims your team has already approved.

HCP content and congress strategy

Content for physicians built on published data and the voices of their peers, plus a plan for the congresses that matter in your therapy area: abstracts, symposia, meetings booked in advance and follow-up content for the weeks after.

ABM into named pharma accounts

For CROs, CDMOs and pharma tech, we score target sponsors on pipeline, modality and outsourcing history, then reach R&D, procurement and quality with LinkedIn, content and BD outreach. Cradle reached scientists at top EU and US pharma companies this way.

Clinical trial recruitment support

Patient and site recruitment campaigns that stay within your protocol and ethics approvals: landing pages, prescreening forms and paid search and social, with each referral tracked to the site that received it.

Compliant pharma digital

Paid search, SEO and email run for a regulated category: approved claims only, platform healthcare ad policies checked before launch, and reporting your compliance team can audit line by line.

The rule we work by

If a claim can't point to its reference, it never reaches your reviewers.

Results

Results for life science and healthcare companies

Life science
Cradle sells AI software for protein design to scientists at large pharma companies in Europe and the US. Its CEO's LinkedIn became the center of a thought leadership program, backed by paid campaigns aimed at its top pharma accounts.
10,000+
organic engagements in the first weeks of the campaigns
60+
high-potential interactions passed to sales every quarter
Healthcare AI
Coforix sells generative AI for hospital administration, and each product has its own buyer. Its first ABM program with us mapped who feels the problem, who holds the budget and who signs, and aimed campaigns at all three.
165
high-intent target contacts active on LinkedIn
27
engaged leads ready for sales

Both clients sell to scientific or clinical buyers, and every number here comes from their published case studies.

What do they say?

We like to let our customers do the talking.

Your journey

Your first 90 days,
week by week

Every pharma client gets a separate plan, which your Head of Growth shapes around your modality, your sponsors and your review process. The cards show one example: a CDMO selling development and manufacturing services to biotech and pharma sponsors.

Kick off
●
Day 0

We meet your CEO, your head of business development and whoever signs off on regulatory and quality claims. Access to the website, CRM and ad accounts follows, and we agree how pipeline will be reported by sponsor and by service.

Onboarding
KPI alignment
Ysabel CamusBerk Kalyoncu
Full audit
●
Weeks 1-2

We interview a handful of sponsors about how they shortlisted you, read recent proposals and lost RFPs, check your claims against their references, and review your site, your search and AI-search visibility and your CRM data.

Sponsor interviews
Claims check
CRM review
Michaela RiesBerk KalyoncuYsabel Camus
Strategy & workshops
●
Weeks 3-4

Two workshops with your leadership and scientific leads settle the modalities and services you lead with, which experts speak for the company, and which sponsors go on the target list.

Positioning
Scientific voices
Sponsor list
Ysabel CamusMichaela RiesBerk Kalyoncu
Quick wins
●
Weeks 4-5

We rewrite the service pages sponsors read first, set up the claims library with your quality team, and route every RFP request from the site into the CRM with its source.

Service pages
Claims library
RFP routing
Berk KalyoncuAlexandru Cojuhari
Modality pages go live
●
Week 6+

A page for each modality and service goes live, showing the equipment, scale, regulatory track record and case examples sponsors check before they send an RFP.

Modality pages
Case examples
AI search
Michaela RiesDaniela GutuAlexandru Cojuhari
Scientific content
●
Week 6+

Your scientists' expertise becomes webinars, application notes and LinkedIn posts. We draft them from short interviews, and the scientists review each piece before it is published.

Webinars
Application notes
Expert posts
Michaela RiesYsabel Camus
Sponsor ABM
●
Week 6+

LinkedIn campaigns and content reach R&D, procurement and quality leads at your target sponsors, and business development calls the accounts that respond.

Target sponsors
LinkedIn ads
BD follow-up
Berk KalyoncuYsabel Camus
Congress and partnering plan
●
Week 6+

We plan the next congresses and partnering events around the sponsors on your list, with meetings booked before each event and a follow-up sequence for the sponsors you met.

Event shortlist
Booked meetings
Follow-up
Ysabel CamusBerk Kalyoncu
First pipeline report
●
Month 3

Your leadership gets one report from the CRM: sponsors engaged, RFPs received and proposals sent, with their value by service line and the source of each. Sponsor decisions take months, so the report also shows which target accounts are getting closer to an RFP.

Sponsors engaged
RFPs received
Pipeline value
Ysabel CamusBerk Kalyoncu
?
After day 90

When the quarter ends, we review the results with your leadership, move budget toward the services and channels that brought in RFPs, and pause the rest.

Review with you
Plan adjusted

Pharma marketing
and the rest of life sciences

Pharma, biotech and life science tools companies often sell to the same scientists, under different rules and with different proof.

You are here

Pharma and pharma services

Buyer: brand and commercial teams at biopharma companies, and R&D, procurement and quality at sponsors. Proof: published data, approved claims and work for comparable sponsors.

Biotech

Platforms and pipelines

Biotech and TechBio companies selling platforms and partnerships to pharma have their own page, built around scientific credibility and partnering.

Life sciences

Tools, reagents and lab software

Companies selling instruments, reagents and software to labs and CROs are covered on our life science page.

Who you'll work with

Meet the people
behind the work.

Team
Ysabel Camus
Ysabel Camus
Head of Growth
James Eisner
James Eisner
Head of Growth
Michaela Ries
Michaela Ries
SEO / GEO Lead
Berk Kalyoncu
Berk Kalyoncu
Performance Specialist
Daniela Gutu
Daniela Gutu
Graphic Designer
Alexandru Cojuhari
Alexandru Cojuhari
Front End & Web Developer
André Antunes
André Antunes
RevOps & AI Lead
Daniel Bilici
Daniel Bilici
Sr. Growth Marketing Manager
Ungated report · Marketing for the Health Tech Industry in 2026

Selling to pharma, from people who have done it.

Marketing for the Health Tech Industry in 2026 report cover

Our health tech report has a section on pharma as a buyer, drawn from James Eisner's experience selling to pharma companies: who holds the budget, why the digital health team is usually the way in, and what evidence gets a vendor considered.

~50
pharma companies really matter as buyers worldwide, so every relationship counts
5 yrs
the longest pharma deal cycle in James's experience, while the shortest took six months
Read the report
The full report is free to read, and the pharma material starts in section two.
FAQ

Pharma marketing agency: questions we get asked

Where we work

Amsterdam and New York, for biopharma, CROs, CDMOs and pharma tech companies selling in Europe or the US.

What does a pharma marketing agency do?
How do you choose between pharmaceutical marketing agencies?
What pharma marketing services do you offer?
How do you handle MLR review and promotional compliance?
Do you work with CROs and CDMOs?
How much does a pharma marketing agency cost?
Can you support clinical trial recruitment?
Are you a pharma digital agency or a full-service partner?
Which pharma companies have you worked with?

Your first call is with a co-founder

The call is 30 minutes with the founder who has the most experience in your industry.

Book a 30-minute call